There is a progressive loss of anti-HER2 Th1 immunity in HER2 positive BC, where healthy donors and patients with HER2 negative BC have preserved HER2-specific Th1 response, compared to a deficient Th1 response in patients with HER2 positive DCIS, and a nearly absent response in women with HER2 positive IBC (Datta et al., 2015c; Figure 1). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.